Ovarian cancer
Ovarian cancer is one of the common tumors of female reproductive organs, and its incidence rate ranks third after cervical cancer and uterine body cancer. However, deaths caused by ovarian cancer account for the first place among all kinds of gynecological tumors, posing a serious threat to women's lives. Due to the complex embryonic development, tissue anatomy and endocrine function of the ovaries, the tumors it suffers from may be benign or malignant. Since ovarian cancer has no symptoms in the early clinical stage, it is quite difficult to distinguish its tissue type and benign or malignant. During laparotomy for ovarian cancer, only 30% of the tumors are found to be confined to the ovaries, and most of them have spread to the uterus, bilateral adnexa, greater omentum and pelvic organs. Therefore, ovarian cancer is indeed a big problem in both diagnosis and treatment. Over the years, experts have conducted many discussions on the pathological morphology, clinical occurrence and development rules and treatment plans of ovarian malignant tumors, and accumulated a lot of experience. So far, according to clinical data statistics at home and abroad, its five-year survival rate is only 25% to 30%.
-
Site of disease:
Ovaries
-
Infectious :
Not contagious
-
Frequent population:
Women aged 30 to 60, mostly occur in perinatal...
-
Related symptoms:
Menstrual disorders
weight loss
lower abdominal pain
lower abdominal mass
postmenopausal bleeding
-
Concurrent disease:
Related Drugs
Topotecan Hydrochloride for Injection
Indication: Small cell lung cancer. Advanced metastatic ovarian cancer who have failed first-line chemotherapy.
Manufacturer:
Yangtze River Pharmaceutical (Group) Co., Ltd.
Paclitaxel Liposomal Injection
Indication: 1. This product can be used for first-line chemotherapy of ovarian cancer and the treatment of ovarian metastatic cancer in the future. As first-line chemotherapy, this product can also be used in combination with cisplatin. 2. This product can also be used for follow-up treatment of breast cancer patients who have used standard chemotherapy containing doxorubicin or for the treatment of recurrent patients. 3. This product can be combined with cisplatin as first-line chemotherapy for patients with non-small cell lung cancer who cannot undergo surgery or radiotherapy.
Manufacturer:
Nanjing Sike Medicine Industry Co., Ltd.
Topotecan Hydrochloride
Indication: For the treatment of metastatic ovarian cancer after failure of first-line chemotherapy or subsequent chemotherapy.
Topotecan Hydrochloride
Indication: For the treatment of metastatic ovarian cancer after failure of first-line chemotherapy or subsequent chemotherapy.
Carboplatin for injection
Indication: It is mainly used for ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, seminoma, bladder cancer, mesothelioma, etc.
Manufacturer:
Cisen Pharmaceutical Co., Ltd.
Carboplatin for injection
Indication: It is mainly used for ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, seminoma, bladder cancer, mesothelioma, etc.
Manufacturer:
Yangtze River Pharmaceutical (Group) Co., Ltd.
Carboplatin for injection
Indication: It is mainly used for ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, seminoma, bladder cancer, mesothelioma, etc.
Carboplatin for injection
Indication: It is mainly used for ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, seminoma, bladder cancer, mesothelioma, etc.
Manufacturer:
Zhejiang Hisun Pharmaceutical Co., Ltd.
Carboplatin for injection
Indication: It is mainly used for ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, seminoma, bladder cancer, mesothelioma, etc.
Carboplatin for injection
Indication: It is mainly used for ovarian cancer, small cell lung cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, seminoma, bladder cancer, mesothelioma, etc.
Manufacturer:
RenHe Hetero Pharmaceuticals Ltd.